Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for COVID-related depression and burnout in clinicians
NCT05163496Phase 3Completed
- Sponsor
- University of Washington
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of psilocybin in major depressive disorder (MDD), burnout syndrome, sponsored by University of Washington. Started Mar 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)burnout syndrome
Beyond the preview
Go deeper on NCT05163496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163496.